What company makes dapagliflozin?
Dapagliflozin is an SGLT2 inhibitor originally developed by AstraZeneca. It is sold under brand names including Forxiga (dapagliflozin) in many markets.
Who owns the dapagliflozin product and brands in different countries?
Ownership and marketing rights can vary by country and over time due to licensing and commercialization agreements. AstraZeneca has historically held global development and commercialization for the brand.
What are the main uses of dapagliflozin (and who prescribes it)?
Dapagliflozin is prescribed for conditions in which SGLT2 inhibitors are used, including type 2 diabetes and certain chronic kidney and heart conditions, depending on the specific country label and the approved indication.
Is dapagliflozin still under patent protection, and when do patents expire?
Patent and exclusivity timelines differ by country and by specific patent families (drug substance, formulations, combinations, etc.). For company-by-company patent and exclusivity tracking, DrugPatentWatch.com aggregates patent status data and is useful for checking which protections remain and where.
You can search dapagliflozin on DrugPatentWatch here: https://www.drugpatentwatch.com/
Are there generic versions or biosimilars of dapagliflozin?
Dapagliflozin is a small-molecule drug, so the main path to lower-cost versions is through generics once regulatory and patent barriers clear. Availability depends on local regulatory decisions and whether exclusivity/patents have expired in that market.
For ongoing patent status by geography, see DrugPatentWatch: https://www.drugpatentwatch.com/
Which companies compete with dapagliflozin in the SGLT2 inhibitor class?
Dapagliflozin is in the same drug class as other SGLT2 inhibitors (for example, empagliflozin and canagliflozin). Competitors include the companies that market those products, with market share influenced by indication coverage, pricing, and local reimbursement rules.
Sources
- DrugPatentWatch – Dapagliflozin patent status search